US-based global CRO/CDMO Frontage Laboratories Inc, a subsidiary of Frontage Holdings Corporation (HKEX:1521), announced on Wednesday that it has acquired Teddy Clinical Research Laboratory (Shanghai) Ltd, a clinical research laboratory service provider in China.

This addition aims to improve Frontage's global laboratory service capabilities and further strengthen its presence in China and the Asia-Pacific region.

Teddy Lab has supported more than 1,500 clinical trials across multiple therapeutic areas and contributed to the successful marketing approval of 50 new drugs. The company is known for its GCP-compliant operations and internationally accredited laboratory services. It operates under CAP-accredited and NGSP Level 1 certified quality systems, as well as qualification as a Class II Unsealed Radioactive Material Workplace, providing pharmaceutical and biotechnology partners with audit-ready laboratory services that meet global regulatory standards.

As a result of the transaction, Frontage has expanded its central laboratory footprint in China, which it expects to leverage in supporting the increasing demand for both domestic China and multi-regional clinical trials. Teddy Lab's central laboratory expertise will be integrated with Frontage's comprehensive service platform, including bioanalytical, DMPK, safety and toxicology, CMC, and clinical trial support.